Loading...
Defiance Next Gen Altered Experience ETF
PSY•AMEX
Financial ServicesAsset Management
$5.90
$-0.03(-0.51%)
Defiance Next Gen Altered Experience ETF (PSY) Stock Overview
Explore Defiance Next Gen Altered Experience ETF’s financial performance, market position, analyst ratings, and future outlook.
Stats data is not available for PSYStats details for PSY are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for PSYAnalyst Recommendations details for PSY are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
The index is a rules-based index that tracks the performance of a portfolio of companies conducting legal activities under the national laws of the applicable country related to medical psychedelics, medical cannabis, cannabis pharmaceuticals and cannabidiol derivatives, and ketamine. The fund uses a “replication” strategy to achieve its investment objective, it will invest in all of the component securities of the index in the same approximate proportions as in the index. It is non-diversified.
Headquarters
DE
Founded
2021